10x Genomics Lowers FY24 Sales Guidance From $640M-$660M Vs. $663.06M Estimate
Portfolio Pulse from Benzinga Newsdesk
10x Genomics has lowered its full-year 2024 sales guidance to a range of $640 million to $660 million, down from the previous range of $670 million to $690 million. This new guidance is below the $663.06 million estimate and represents a 3% to 7% growth over 2023 revenue.
August 08, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
10x Genomics has revised its full-year 2024 sales guidance downward to $640 million to $660 million, which is below the market estimate of $663.06 million. This adjustment indicates a slower growth rate than previously anticipated.
The downward revision in sales guidance suggests that 10x Genomics may face challenges in achieving its previously anticipated growth. This is likely to result in negative sentiment among investors, leading to short-term pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100